Corrigendum to “Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: A role for NF-κB–STAT3-directed gene expression” [Exp. Cell Res. 317 (2011) 1548–1566] (Experimental Cell Research (2011) 317(11) (1548–1566), (S0014482711001042), (10.1016/j.yexcr.2011.03.012));Radiation response and regulation of apoptosis induced by a combination of TRAIL and CHX in cells lacking mitochondrial DNA: A role for NF-κB-STAT3-directed gene expression

Experimental Cell Research

Volumn 317, Issue 11, 2011, Pages 1548-1566

  Ivanov, Vladimir N ^a   Ghandhi, Shanaz A ^a   Zhou, Hongning ^a   Huang, Sarah X ^a   Chai, Yunfei ^a   Amundson, Sally A ^a   Hei, Tom K ^a  

^a Columbia University ^*  (United States)

Author keywords

Apoptosis; IL6; Mitochondria; NF B; STAT3; TRAIL

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; CYCLOHEXIMIDE; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 28B; INTERLEUKIN 31 RECEPTOR A; INTERLEUKIN 6; JANUS KINASE 2; MACROPHAGE ELASTASE; MESSENGER RNA; MITOCHONDRIAL DNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN; PROTEIN IGFL2; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; STAT3 PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; IRRADIATION; PRIORITY JOURNAL; RADIATION RESPONSE; SIGNAL TRANSDUCTION;

EID: 79956323620     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2021.112776     Document Type: Erratum

References (65)

1. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26:3621-3630.
2. Jin Z., El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 2005, 4:139-163.
3. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
4. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64:337-346.
5. Ivanov V.N., Zhou H., Hei T.K. Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells. Cancer Res. 2007, 67:5397-5407.
6. Hersey P., Zhang X.D. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunol. Immunother. 2009, 58:1749-1759.
7. Costantini P., Jacotot E., Decaudin D., Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J. Natl Cancer Inst. 2000, 92:1042-1053.
8. Debatin K.M., Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 2004, 23:2950-2966.
9. Jones R.G., Thompson C.B. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009, 23:537-548.
10. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria as targets for cancer chemotherapy. Semin. Cancer Biol. 2009, 19:57-66.
11. Adams J.M., Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr. Opin. Immunol. 2007, 19:488-496.
12. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
13. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol. 2008, 18:165-173.
14. King M.P., Koga Y., Davidson M., Schon E.A. Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Mol. Cell. Biol. 1992, 12:480-490.
15. Jacobson M.D., Burne J.F., King M.P., Miyashita T., Reed J.C., Raff M.C. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993, 361:365-369.
16. Wang J., Silva J.P., Gustafsson C.M., Rustin P., Larsson N.G. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc. Natl Acad. Sci. U. S. A. 2001, 98:4038-4043.
17. Schulze-Osthoff K., Beyaert R., Vandevoorde V., Haegeman G., Fiers W. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J. 1993, 12:3095-3104.
18. Jiang S., Cai J., Wallace D.C., Jones D.P. Cytochrome c-mediated apoptosis in cells lacking mitochondrial DNA. Signaling pathway involving release and caspase 3 activation is conserved. J. Biol. Chem. 1999, 274:29905-29911.
19. Santamaria G., Martinez-Diez M., Fabregat I., Cuezva J.M. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006, 27:925-935.
20. Dey R., Moraes C.T. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J. Biol. Chem. 2000, 275:7087-7094.
21. Park S.Y., Chang I., Kim J.Y., Kang S.W., Park S.H., Singh K., Lee M.S. Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J. Biol. Chem. 2004, 279:7512-7520.
22. Zhou H., Ivanov V.N., Lien Y.C., Davidson M., Hei T.K. Mitochondrial function and nuclear factor-kappaB-mediated signaling in radiation-induced bystander effects. Cancer Res. 2008, 68:2233-2240.
23. Liu S.X., Davidson M.M., Tang X., Walker W.F., Athar M., Ivanov V., Hei T.K. Mitochondrial damage mediates genotoxicity of arsenic in mammalian cells. Cancer Res. 2005, 65:3236-3242.
24. Zhou H., Randers-Pehrson G., Waldren C.A., Vannais D., Hall E.J., Hei T.K. Induction of a bystander mutagenic effect of alpha particles in mammalian cells. Proc. Natl Acad. Sci. U. S. A. 2000, 97:2099-2104.
25. Wright G.W., Simon R.M. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 2003, 19:2448-2455.
26. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 1995, 57:289-300.
27. Ghandhi S.A., Yaghoubian B., Amundson S.A. Global gene expression analyses of bystander and alpha particle irradiated normal human lung fibroblasts: synchronous and differential responses. BMC Med. Genomics 2008, 1:63.
28. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3.
29. Thomas P.D., Campbell M.J., Kejariwal A., Mi H.Y., Karlak B., Daverman R., Diemer K., Muruganujan A., Narechania A. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13:2129-2141.
30. Partridge M.A., Huang S.X., Hernandez-Rosa E., Davidson M.M., Hei T.K. Arsenic induced mitochondrial DNA damage and altered mitochondrial oxidative function: implications for genotoxic mechanisms in mammalian cells. Cancer Res. 2007, 67:5239-5247.
31. Erez N., Truitt M., Olson P., Arron S.T., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
32. Alexeyev M.F., Ledoux S.P., Wilson G.L. Mitochondrial DNA and aging. Clin. Sci. (Lond.) 2004, 107:355-364.
33. Dauer D.J., Ferraro B., Song L., Yu B., Mora L., Buettner R., Enkemann S., Jove R., Haura E.B. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005, 24:3397-3408.
34. Snyder M., Huang X.Y., Zhang J.J. Identification of novel direct Stat3 target genes for control of growth and differentiation. J. Biol. Chem. 2008, 283:3791-3798.
35. Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., Wu P., Wiesmann C., Baker R., Boone D.L., Ma A., Koonin E.V., Dixit V.M. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004, 430:694-699.
36. Kim J.W., Tchernyshyov I., Semenza G.L., Dang C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3:177-185.
37. Groner A.C., Meylan S., Ciuffi A., Zangger N., Ambrosini G., Denervaud N., Bucher P., Trono D. KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. PLoS Genet. 2010, 6:e1000869.
38. Amundson S.A., Grace M.B., McLeland C.B., Epperly M.W., Yeager A., Zhan Q., Greenberger J.S., Fornace A.J. Human in vivo radiation-induced biomarkers: gene expression changes in radiotherapy patients. Cancer Res. 2004, 64:6368-6371.
39. Smirnov D.A., Morley M., Shin E., Spielman R.S., Cheung V.G. Genetic analysis of radiation-induced changes in human gene expression. Nature 2009, 459:587-591.
40. V.N. Ivanov, H. Zhou, S.A. Ghandhi, T.B. Karasic, B. Yaghoubian, S.A. Amundson, T.K. Hei, Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell. Signal. 22 (2010) 1076-1087.
41. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
42. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
43. Grivennikov S., Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 2008, 13:7-9.
44. Ivanov V.N., Zhou H., Ghandhi S.A., Karasic T.B., Yaghoubian B., Amundson S.A., Hei T.K. Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell. Signal. 2010, 22:1076-1087.
45. Sahin E., Colla S., Liesa M., Moslehi J., Muller F.L., Guo M., Cooper M., Kotton D., Fabian A.J., Walkey C., Maser R.S., Tonon G., Foerster F., Xiong R., Wang Y.A., Shukla S.A., Jaskelioff M., Martin E.S., Heffernan T.P., Protopopov A., Ivanova E., Mahoney J.E., Kost-Alimova M., Perry S.R., Bronson R., Liao R., Mulligan R., Shirihai O.S., Chin L., Depinho R.A. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011, 470:359-365.
46. Boyer P.D. The ATP synthase-a splendid molecular machine. Annu. Rev. Biochem. 1997, 66:717-749.
47. Ferri K.F., Kroemer G. Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 2001, 3:E255-E263.
48. Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
49. Pelicano H., Xu R.H., Du M., Feng L., Sasaki R., Carew J.S., Hu Y., Ramdas L., Hu L., Keating M.J., Zhang W., Plunkett W., Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell Biol. 2006, 175:913-923.
50. Lu J., Sharma L.K., Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009, 19:802-815.
51. Froehlich T.E., Lanphear B.P., Dietrich K.N., Cory-Slechta D.A., Wang N., Kahn R.S. Interactive effects of a DRD4 polymorphism, lead, and sex on executive functions in children. Biol. Psychiatry 2007, 62:243-249.
52. Bubici C., Papa S., Dean K., Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006, 25:6731-6748.
53. Karin M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol. 2009, 1:a000141.
54. Kumar A., Takada Y., Boriek A.M., Aggarwal B.B. Nuclear factor-kappaB: its role in health and disease. J. Mol. Med. 2004, 82:434-448.
55. Kusaba M., Nakao K., Goto T., Nishimura D., Kawashimo H., Shibata H., Motoyoshi Y., Taura N., Ichikawa T., Hamasaki K., Eguchi K. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis. J. Hepatol. 2007, 47:546-555.
56. Kovalovich K., Li W., DeAngelis R., Greenbaum L.E., Ciliberto G., Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem. 2001, 276:26605-26613.
57. Ivanov V.N., Bhoumik A., Krasilnikov M., Raz R., Owen-Schaub L.B., Levy D., Horvath C.M., Ronai Z. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol. Cell 2001, 7:517-528.
58. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21:1396-1408.
59. Iliopoulos D., Hirsch H.A., Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
60. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
61. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., Derecka M., Szczepanek K., Szelag M., Gornicka A., Moh A., Moghaddas S., Chen Q., Bobbili S., Cichy J., Dulak J., Baker D.P., Wolfman A., Stuehr D., Hassan M.O., Fu X.Y., Avadhani N., Drake J.I., Fawcett P., Lesnefsky E.J., Larner A.C. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
62. Ivanov V.N., Partridge M.A., Huang S.X., Hei T.K. Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis. J. Cell. Biochem. 2011, 112:463-475.
63. J. Yang, R. Splittgerber, F.E. Yull, S. Kantrow, G.D. Ayers, M. Karin, A. Richmond, Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J. Clin. Invest. 120 (2010) 2563-2574.
64. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
65. Durieux J., Wolff S., Dillin A. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 2011, 144:79-91.